Fluticasone Propionate
Top news of November: Metformin use in asthma, impact of Flovent discontinuation
Healio has compiled the most-read news in pulmonology posted in November.
ICU, inpatient admission rates related to asthma rise following Flovent discontinuation
Following the discontinuation of Flovent in January, ICU admissions, inpatient admissions and ED visits related to asthma rose in comparison with previous years, according to study results from Epic Research.
Top in allergy/asthma: FDA OKs Xhance; acid-suppressive therapy linked with food allergy
The FDA approved Xhance for the treatment of chronic rhinosinusitis without nasal polyps among patients aged 18 years and older.
FDA OKs fluticasone propionate nasal spray for chronic rhinosinusitis without nasal polyps
The FDA has approved fluticasone propionate nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients aged 18 years and older, according to an Optinose press release.
Inhaled corticosteroid confers modest improvement in lung function in preterm-born children
Among preterm-born children, treatment with fluticasone propionate for 12 weeks led to a modest improvement in lung function, researchers reported at the European Respiratory Society International Congress.
Exhalation delivery system reduces chronic sinusitis symptoms, inflammation
Fluticasone propionate nasal spray reduced the symptoms of chronic sinusitis and local inflammation of the nasal cavity and adjacent sinus cavities, according to topline study results from pharmaceutical company OptiNose.